Evidence map›Paper›PMID 31592294›Full record

ArticlePharmacy practice

A descriptive study of antithrombotic medication patterns in adult patients with recent venous thromboembolism.

Fady Allahwerdy, Steven Pan, Michael Feehan, Aubrey E Jones, Mark A Munger, Daniel M Witt

Abstract read
In one paragraph

Article in Pharmacy practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fady AllahwerdyDepartment of Pharmacotherapy, College of Pharmacy, University of Utah. Salt Lake City, UT (United States). fady.allahwerdy@pharm.utah.edu.ORCID 0000-0001-8158-2935
Steven PanDepartment of Pharmacotherapy, College of Pharmacy, University of Utah. Salt Lake City, UT (United States). steven.pan@pharm.utah.edu.ORCID 0000-0003-4511-7598
Michael FeehanKantar LLC, San Francisco, CA (United States). michael.feehan@kantar.com.ORCID 0000-0002-3921-1089
Aubrey E JonesThrombosis Service, University of Utah Health; & Department of Pharmacotherapy, College of Pharmacy, University of Utah. Salt Lake City, UT (United States). aubrey.e.jones@pharm.utah.edu.ORCID 0000-0003-1726-702X
Mark A MungerDepartment of Pharmacotherapy, College of Pharmacy; & Department of Internal Medicine, School of Medicine, University of Utah. Salt Lake City, UT (United States). mark.munger@hsc.utah.edu.ORCID 0000-0001-9543-1898
Daniel M WittThrombosis Service, University of Utah Health; & Department of Pharmacotherapy, College of Pharmacy, University of Utah. Salt Lake City, UT (United States). dan.witt@pharm.utah.edu.ORCID 0000-0002-3930-8358

Funding

Utah Center for Clinical and Translational ScienceUL1TR002538 · NCATS · UNIVERSITY OF UTAH · PI HESS, RACHEL, MAJERSIK, JENNIFER JUHL · 2018 to 2022
$26.0M
NCATS NIH HHS UL1 TR002538
6 · The paper itself

Abstract

objectivesThe objective of this study is to describe the most common self-reported antithrombotic therapy utilization patterns in a national cohort of patients with recent venous thromboembolism (VTE).

methodsExtant data from a national online survey administered to 907 patients 18 years of age or older with VTE in the last two years were analyzed. Patients' self-reported antithrombotic usage patterns used during three phases of treatment for the most recent VTE episode were summarized using descriptive statistics.

resultsThe following overall antithrombotic usage patterns were identified: warfarin (38.7%), direct oral anticoagulants (DOACs) (26.1%), switching between warfarin and DOACs (13.3%), aspirin only (8.7%), switching between different DOACs (4.5%), injectable anticoagulants only (3.9%), and no treatment (4.7%). Extended antithrombotic therapy beyond 90 days was reported by 65.7% of patients. Aspirin coadministration with anticoagulant therapy occurred for 33.7%.

conclusionsIn this national sample of recent VTE sufferers warfarin therapy remains the most used anticoagulant followed closely by DOAC therapy. Switching between warfarin and DOACs and between different DOACs was common which could indicate adverse events or affordability issues. Aspirin coadministration with anticoagulant therapy was present in 1 of 3 patients and is a potential medication safety intervention for anticoagulation providers.

Indexed as

AnticoagulantsCohort StudiesDrug UtilizationPhysicians’Practice PatternsThrombolytic TherapyUtahVenous Thromboembolism

Identifiers

PMID31592294
PMCPMC6763305

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.